Celgene Prices $8B Note Offering To Back Receptos Deal
New Jersey biopharmaceutical company Celgene Corp. said on Tuesday that it has successfully priced five unsecured senior notes series for $8 billion in an effort to fund its $7.2 billion acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article